Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study
Sign Up to like & getrecommendations! Published in 2021 at "Gynecologic Oncology"
DOI: 10.1016/s0090-8258(21)00758-7
Abstract: Objectives: Anlotinib is a novel multi-target tyrosine kinase inhibitor for tumor angiogenesis and proliferative signaling. A previous retrospective study achieved the overall response rate (ORR) of 14.3% and the disease control rate (DCR) of 85.7%… read more here.
Keywords: resistant ovarian; combined pemetrexed; anlotinib combined; ovarian cancer ... See more keywords